medigraphic.com

2022, Número 4

<< Anterior Siguiente >>

Rev Educ Bioquimica 2022; 41 (4)


El proteosoma: su interregulación con el citoesqueleto de actina y sus alteraciones en patologías

Martínez PD, Gómez CKA, Sosa GM, Macías SM

Idioma: Español
Referencias bibliográficas: 43
Paginas: 140-153
Archivo PDF: 576.99 Kb.


RESUMEN

La proteostasis u homeostasis de las proteínas es un proceso importante para la función normal de las células, en el cual la degradación de proteínas es clave. El Sistema Ubicuitina-Proteosoma (UPS) es uno de los principales mecanismos a cargo de la degradación de múltiples proteínas celulares. El funcionamiento adecuado y eficiente del UPS depende de una fuerte y estricta regulación en su ensamblado. Cambios en la polaridad celular y en la dinámica del citoesqueleto de actina se relacionan con la regulación en la estabilidad de las proteínas, al controlar a algunos componentes del UPS. Esta revisión resume y analiza la información reciente sobre la interregulación del proteosoma con la dinámica del citoesqueleto de actina con el fin de entender su relevancia en la homeostasis celular. Además, incluye evidencia de que el mal funcionamiento del UPS conduce al desarrollo de diversas enfermedades humanas, por lo que actualmente el proteosoma se considera un importante blanco terapéutico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Budenholzer L, Cheng CL, Yanjie, HochstrasserM. Proteasome Structure and Assembly, J MolBiol. 2017; 429 (22):3500-24.

  2. Ciechanover A, Ben-Saadon R. N-terminalubiquitination: more protein substrates joinin, Trends Cell Biol. 2004; 14 (3):103-6.

  3. Rousseau A, Bertolotti A. Regulation ofproteasome assembly and activity in healthand disease, Nat Rev Mol Cell Biol. 2018; 19(11):697-712.

  4. Pickar t CM. Mechanisms under lyingubiquitination, Annu Rev Biochem. 2001;70:503-33.

  5. Yau R. Rape M. The increasing complexity ofthe ubiquitin code, Nat Cell Biol. 2016; 18(6):579-86.

  6. Bard JAM, Goodall EA, Greene ER, Jonsson E,Dong KC, Martin A. Structure and Functionof the 26S Proteasome, Annu Rev Biochem.2018; 87:697-724.

  7. Kunjappu MJ, Hochstrasser M. Assembly ofthe 20S proteasome, Biochim Biophys Acta.2014; 1843 (1):2-12.

  8. Wójcik C, De Martino GN. Intracellularlocalization of proteasomes, Int J BiochemCell Biol. 2003; 35 (5):579-89.

  9. Enenkel C, Lehmann A, Kloetzel PM. GFPlabellingof 26S proteasomes in living yeast:insight into proteasomal functions at thenuclear envelope/rough ER, Mol Biol Rep.1999; 26 (1-2) :131–5.

  10. Wilkinson CR, Wallace M, Morphew M, Perry P,Allshire R, Javerzat JP, McIntosh JR, GordonC. Localization of the 26S proteasome duringmitosis and meiosis in fission yeast, EMBO J.1998; 17 (22):6465–76.

  11. Machiels BM, Henfling ME, Broers JL, HendilKB, Ramaekers FC. Changes in immunocytochemicaldetectability of proteasomeepitopes depending on cell growth and fixationconditions of lung cancer cell lines, Eur J CellBiol. 1995; 66 (3):282-92.

  12. Wang Y, Le WD. Autophagy and Ubiquitin-Proteasome System, Adv Exp Med Biol 2019;1206:527-50.

  13. Van Deventer S, Menendez-Benito V, vanLeeuwen F, Neefjes J. N-terminal acetylationand replicative age affect proteasomelocalization and cell fitness during aging, JCell Sci. 2015; 128 (1):109-17.

  14. Im E, Chung KC. Precise assembly andregulation of 26S proteasome and correlationbetween proteasome dysfunction andneurodegenerative diseases, BMB Rep. 2016;49 (9):459-73.

  15. Bose S, Stratford FLL, Broadfoot KI, MasonGGF, Rivett AJ. Phosphorylation of 20Sproteasome alpha subunit C8 (α7) stabilizesthe 26S proteasome and plays a role inthe regulation of proteasome complexesby γ–interferon, Biochem. J. 2004; 378 (Pt1):177–84.

  16. Lin JT, Chang WC, Chen HM, Lai HL, ChenCY, Tao MH, Chern Y. Regulation of feedbackbetween protein kinase A and the proteasomesystem worsens Huntington’s disease, Mol CellBiol. 2013; 33 (5):1073-84.

  17. VerPlank JJS, Lokireddy S, Zhao J, GoldbergAL. 26S proteasomes are rapidly activated bydiverse hormones and physiological states thatraise cAMP and cause Rpn6 phosphorylation,Proc Natl Acad Sci USA. 2019; 116 (10):4228-37.

  18. Collins GA, Goldberg AL. The Logic of the 26SProteasome, Cell. 2017; 169 (5):792-806.

  19. Liu X, Xiao W, Zhang Y, Wiley SE, Zuo T, ZhengY, Chen N, Chen L, Wang X, Zheng Y, HuangL, Lin S, Murphy AN, Dixon JE, Xu P, Guo X.Reversible phosphorylation of Rpn1 regulates26S proteasome assembly and function, ProcNatl Acad Sci U S A. 2020; 117 (1):328-36.

  20. Onishi M, Pecani K, Jones 4th T, PringleJR, Cross F. F-actin homeostasis throughtranscriptional regulation and proteasomemediatedproteolysis, Proc Natl Acad Sci U SA. 2018; 115 (28):E6487-96.

  21. Plessner M, Melak M, Chinchilla P, BaarlinkC, Grosse R. Nuclear F-actin formation andreorganization upon cell spreading, J BiolChem. 2015; 290 (18):11209-16.

  22. Kelpsch DJ, Tootle TL. Nuclear Actin: FromDiscovery to Function, Anat Rec (Hoboken).2018; 301 (12):1999-2013.

  23. Bórquez DA, González-Billault C. Regulation ofcell polarity by controlled proteolytic systems,Biol Res. 2011; 44 (1):35-41.

  24. Ibañez-Vega J, Del Valle Batalla F, Saez JJ,Soza A, Yuseff MI. Proteasome DependentActin Remodeling Facilitates Antigen Extractionat the Immune Synapse of B Cells, FrontImmunol. 2019; 10:225.

  25. Caligaris C, Vázquez-Victorio G, Sosa-GarrochoM, Ríos-López DG, Marín-Hernández A, Macías-Silva M. Actin-cytoskeleton polymerizationdifferentially controls the stability of Ski andSnoN co-repressors in normal but not intransformed hepatocytes, Biochim BiophysActa. 2015; 1850 (9):1832-41.

  26. Vázquez-Victorio G, Caligaris C, Del Valle-Espinosa E, Sosa-Garrocho M, González-Arenas NR, Reyes-Cruz G, Briones-Orta MA,Macías-Silva M. Novel regulation of Ski proteinstability and endosomal sorting by actincytoskeleton dynamics in hepatocytes, J BiolChem. 2015; 290 (7):4487-99.

  27. Melchionna R, Trono P, Tocci A, Nisticò P. ActinCytoskeleton and Regulation of TGF-betaSignaling: Exploring Their Links. Biomolecules.2021; 11 (2):336.

  28. Park JS, Burckhardt CJ, Lazcano R, SolisLM, Isogai T, Li L, Chen CS, Gao B, MinnaJD, Bachoo R, DeBerardinis RJ, DanuserG. Mechanical regulation of glycolysis viacytoskeleton architecture, Nature. 2020; 578(7796):621-626.

  29. Wu HQ, Baker D, Ovaa H. Small moleculesthat target the ubiquitin system, Biochem SocTrans. 2020; 48 (2):479-97.

  30. Senft D, Qi J. and Ronai ZA. Ubiquitin ligasesin oncogenic transformation and cancertherapy, Nature Rev Cancer. 2018; 18 (2):69-88.

  31. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2promotes the rapid degradation of p53,Nature. 1997; 387 (6630):296-9.

  32. Martinez-Zapien D, Ruiz FX, Poirson J,Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande Pol S, PodjarnyA, Travé G, Zanier K. Structure of theE6/E6AP/p53 complex required for HPVmediateddegradation of p53, Nature. 2016;529(7587):541-5.

  33. Ciechanover A, Schwartz AL. Ubiquitinmediateddegradation of cellular proteinsin health and disease, Hepathology. 2002;35(1):3-6.

  34. Popovic D, Vucic D and Dikic I. Ubiquitinationin disease pathogenesis and treatment,Nature Med. 2014; 20 (11):1242–53.

  35. Singleton AB, Farrer M, Johnson J, Singleton A,Hague S, Kachergus J, Hulihan M, PeuralinnaT, Dutra A, Nussbaum R, Lincoln S, CrawleyA, Hanson M, Maraganore D, Adler C, CooksonMR, Muenter M, Baptista M, Miller D, BlancatoJ, Hardy J, Gwinn-Hardy K. alpha-synucleinlocus triplication causes Parkinson’s disease,Science. 2003; 302 (5646):841.

  36. Bertolotti A. The ubiquitin–proteasome systemin neurodegenerative diseases: more thanthe usual suspects, Protein Chaperones andProtection from Neurodegenerative Diseases,First Edition. 2011; by John Wiley & Sons, Inc.

  37. Hao YH, Fountain MD Jr, Fon Tacer K, XiaF, Bi W, Kang SH, Patel A, Rosenfeld JA, LeCaignec C, Isidor B, Krantz ID, Noon SE,Pfotenhauer JP, Morgan TM, Moran R, PedersenRC, Saenz MS, Schaaf CP, Potts PR. USP7 actsas a molecular rheostat to promote WASHdependentendosomal protein recycling andis mutated in a human neurodevelopmentaldisorder, Mol Cell. 2015; 59 (6):956–69.

  38. Grillari J. Post-translational modification ofcellular proteins by ubiquitin and ubiquitinlikemolecules: role in cellular senescenceand ageing, In: Tavernarakis N. (eds) ProteinMetabolism and Homeostasis in Aging, AdvExp Med Biol. 2010; 694:172-96.

  39. Roeten MSF, Cloos J, Jansen G. Positioningof proteasome inhibitors in therapy of solidmalignancies, Cancer Chemother Pharmacol.2018; 81 (2):227-43.

  40. Kisselev AF, Goldberg AL. Proteasomeinhibitors: from research tools to drugcandidates, Chem Biol. 2001; 8 (8):739-58.

  41. Thibaudeau TA, Smith DM A. Practical Reviewof Proteasome, Pharmacol Rev. 2019; 71(2):170-97.

  42. Nunes AT, Annunziata CM. Proteasomeinhibitors: structure and function, SeminOncol. 2017; 44 (6):377-80.

  43. Okazuka K, Ishida T. Proteasome inhibitors formultiple mieloma, Jpn J Clin Oncol. 2018; 48(9):785-93.




2020     |     www.medigraphic.com